Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease

European Journal of Neurology

Volumn 22, Issue 1, 2015, Pages 93-98

  Moccia, M ^a   Picillo, M ^b   Erro, R ^c,d   Vitale, C ^e,f   Longo, K ^e   Amboni, M ^e   Santangelo, G ^g   Palladino, R ^a,h   Capo, G ⁱ   Orefice, G ^a   Barone, P ^b   Pellecchia, M T ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF VERONA   (Italy)

^e IDC Hermitage Capodimonte   (Italy)

^f UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

Author keywords

Biomarker; Non motor; Parkinson; Progression; Urate; Uric

Indexed keywords

BIOLOGICAL MARKER; LEVODOPA; URIC ACID;

ADULT; AGED; ANXIETY; ARTICLE; ATTENTION; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; LEVODOPA EQUIVALENT DAILY DOSAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR DYSFUNCTION; NON MOTOR SYMPTOM; NON MOTOR SYMPTOMS QUESTIONNAIRE; PARKINSON DISEASE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; URIC ACID BLOOD LEVEL; BLOOD; CLASSIFICATION; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; URIC ACID;

EID: 84923089659     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12533     Document Type: Article

References (25)

1. Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord 2008; 23: 1653-1657.
2. Jesús S, Pérez I, Cáceres-Redondo MT, et al. Low serum uric acid concentration in Parkinson's disease in southern Spain. Eur J Neurol 2013; 20: 208-210.
3. The Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurology 2014; 71: 141-150.
4. Alonso A, Gracia Rodriguez LA, Logroscino G, Hernán MA. Gout and risk of Parkinson disease. Neurology 2007; 69: 1696-1700.
5. Winquist A, Steenland K, Shankar A. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord 2010; 25: 932-936.
6. Jain S, Ton TG, Boudreau RM, et al. The risk of Parkinson disease associated with urate in a community-based cohort of older adults. Neuroepidemiology 2011; 36: 223-229.
7. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease. Arch Neurol 2008; 65: 716-723.
8. Ascherio A, LeWitt PA, Xu K, et al. Urate predicts rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460-1468.
9. Annanmaki T, Pohja M, Parviainen T, et al. Uric acid and cognition in Parkinson's disease: a follow-up study. Parkinsonism Relat Disord 2011; 17: 333-337.
10. Chaudhuri RK, Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15(Suppl. 2): 2-7.
11. Moccia M, Picillo M, Erro R, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? Parkinsonism Relat Disord 2014; 20: 772-775.
12. Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 2013; 84: 14-17.
13. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
14. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987: 153-163.
15. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496-503.
16. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
17. Köllensperger M, Geser F, Ndayisaba JP, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Mov Disord 2010; 25: 2604-2612.
18. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9.
19. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9(3 Suppl): 417-423.
20. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
21. Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson's disease? J Geriatr Psychiatry Neurol 2014; 27: 276-281.
22. Kesebir S, Süner O, Yaylaci ET, Bayrak A, Turan C. Increased uric acid levels in bipolar disorder: is it trait or state? J Biol Regul Homeost Agents 2013; 27: 981-988.
23. Lyngdoh T, Bochud M, Glaus J, et al. Associations of serum uric acid and SLC2A9 variant with depressive and anxiety disorders: a population-based study. PLoS One 2013; 8: e76336.
24. Wen S, Cheng M, Wang H, et al. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem 2012; 45: 49-53.
25. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular morbidity and mortality. BMC Nephrology 2013; 14: 161.